论文部分内容阅读
目的观察氨溴索联合头孢哌酮舒巴坦治疗脑卒中获得性肺炎的临床疗效。方法将90例卒中获得性肺炎患者随机分成2组,治疗组42例采用氨溴索联合头孢哌酮舒巴坦,对照组48例采用头孢曲松,比较2组治疗后临床改善情况。结果治疗组与对照组总有效率分别为96%和73%,细菌清除率为93%和71%,两者差异均有统计学意义(P<0.01)。结论氨溴索联合头孢哌酮舒巴坦治疗脑卒中获得性肺炎临床疗效显著。
Objective To observe the clinical efficacy of ambroxol combined with cefoperazone sulbactam in the treatment of stroke-acquired pneumonia. Methods Ninety patients with stroke-acquired pneumonia were randomly divided into two groups: 42 patients in the treatment group received ambroxol and cefoperazone sulbactam, and 48 patients in the control group received ceftriaxone. The clinical improvement was compared between the two groups. Results The total effective rates of the treatment group and the control group were 96% and 73% respectively, and the bacterial clearance rate was 93% and 71% respectively. There was significant difference between the two groups (P <0.01). Conclusion Ambroxol combined with cefoperazone sulbactam has a significant clinical effect on stroke-acquired pneumonia.